Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.54 |
| ▸ | MEN1 | O00255 | 6/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | HBB | P68871 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.37 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16239054 | 0.76 | MAPT (0.52) | MAPTMEN1KMT2AHSD17B10ALOX15 | |
| SCHEMBL31170846 | 0.73 | CRBN (0.44) | MAPTMEN1KMT2AHSD17B10LMNA | |
| SCHEMBL433799 | 0.72 | AHR (0.61) | MAPTCREBBPDAOGRIA1CACNG8 | |
| SCHEMBL31734657 | 0.70 | CREBBP (0.58) | MAPTCREBBPDAOGRIA1CACNG8 | |
| SCHEMBL6238897 | 0.70 | MAPT (1.00) | MAPTMEN1KMT2AHSD17B10ALOX15 | |
| SCHEMBL5444371 | 0.65 | MAPT (0.58) | MAPTMEN1KMT2ALMNAL3MBTL1 | |
| SCHEMBL7527765 | 0.64 | DRD2 (0.38) | MAPTMEN1KMT2AHSD17B10ALOX15 | |
| SCHEMBL434004 | 0.63 | NPC1 (0.50) | MAPTDDB1CRBNCREBBPDAO | |
| SCHEMBL691638 | 0.63 | HTR2C (0.55) | — | |
| SCHEMBL15619572 | 0.63 | TDP2 (0.46) | CREBBPDAOGRIA1CACNG8AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360143-A1 | COMPOSITIONS AND METHODS FOR PHARMACOLOGIC TREATMENT OF STROKE AND MYOCARDIAL ISCHEMIA REPERFUSION INJURY | UNIV CONNECTICUT (US) | 2025-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360143-A1 | COMPOSITIONS AND METHODS FOR PHARMACOLOGIC TREATMENT OF STROKE AND MYOCARDIAL ISCHEMIA REPERFUSION INJURY | PLAT, SERPINE1, SERPINC1 | MAPT 2236/4885MEN1 3434/4885KMT2A 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.